drugset / Trial / NCT00271063
Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II multi-center, open label, dose escalation study to identify the maximum tolerated dose (MTD) of liposomal annamycin and to evaluate the safety of liposomal annamycin in patients with refractory or relapsed acute lymphocytic leukemia.
Timeline
- Start
- 2005-10
- Primary completion
- —
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NAXTARUBICIN | Small molecule | 190 mg/m2 | Intravenous |
| Subject | NAXTARUBICIN | Small molecule | 230 mg/m2 | Intravenous |
| Subject | NAXTARUBICIN | Small molecule | 280 mg/m2 | Intravenous |
| Subject | NAXTARUBICIN | Small molecule | 310 mg/m2 | Intravenous |